VRT – UBS rates the stock as Neutral

By Broker News | More Articles by Broker News

Despite a rebound in the industry growth over January and February, UBS expects a contraction of -3.0% for the domestic cycle in the second half of FY17.

The fourth quarter is expected to be particularly challenging. The broker finds few positive catalysts and retains a Neutral rating. Target is $5.94.

Sector: Health Care Equipment & Services.

Target price is $5.94.Current Price is $5.94. Difference: $0.00 – (brackets indicate current price is over target). If VRT meets the UBS target it will return approximately 0% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →